IceCure Medical Ltd. announced that its application for a new CPT code, describing the use of cryoablation for treating cancerous breast tumors, has been approved by the American Medical Association (AMA). Category III CPT Codes are typically issued for emerging innovative technologies and procedures, to support better tracking in the use of these procedures. These codes also enable providers to apply for reimbursement for procedures using cryoablation therapy for ablating malignant breast tumors. Category III CPT Codes are generally limited to a number of years, until the requirements for a Category I CPT code are met. IceCure expects that the new reimbursement code will provide important support for further adoption of cryoablation therapy for breast cancer. The growing recognition of the role of cryoablation in managing breast cancer is further evidenced by the presentation, in May 2018, of the interim results from the landmark ICE3 clinical study. ICE3 is the controlled multicenter clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them. The company is currently in discussions with the Food and Drug Administration (FDA) to expand the use of its cryoablation system, ProSense™, to enable minimally-invasive cryoablation treatment of cancerous breast tumors. ProSense™ is already cleared by the FDA for use as a non-surgical solution to treat non-cancerous breast tumors (Fibroadenoma) in outpatient and office settings.